Literature DB >> 16502421

High-dose cyclophosphamide without stem cell rescue for refractory multifocal motor neuropathy.

Thomas H Brannagan1, Armin Alaedini, Douglas E Gladstone.   

Abstract

Patients with multifocal motor neuropathy (MMN) respond to intravenous immune globulin (IVIg) and cyclophosphamide, although the benefit is not sustained. High-dose cyclophosphamide can induce a remission in patients with autoimmune diseases, including chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). We describe a patient with refractory MMN who improved with high-dose cyclophosphamide (50 mg/kg for 4 days) without stem cell rescue. Following treatment she discontinued IVIg. At a 6-month examination, her strength had improved and she had regained the ability to write. High-dose cyclophosphamide may be a successful treatment for patients with MMN refractory to other therapies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16502421     DOI: 10.1002/mus.20524

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  6 in total

1.  Diagnosis and treatment of multifocal motor neuropathy.

Authors:  Ryuji Kaji
Journal:  Curr Treat Options Neurol       Date:  2008-03       Impact factor: 3.598

Review 2.  Chronic inflammatory demyelinating polyneuropathies: current treatment strategies.

Authors:  Thomas B Toothaker; Thomas H Brannagan
Journal:  Curr Neurol Neurosci Rep       Date:  2007-01       Impact factor: 5.081

Review 3.  Current and Emerging Pharmacotherapeutic Interventions for the Treatment of Peripheral Nerve Disorders.

Authors:  Jeremy Chung Bo Chiang; Ria Arnold; Roshan Dhanapalaratnam; Maria Markoulli; Arun V Krishnan
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-15

Review 4.  Inflammatory demyelinating neuropathies and neuropathies associated with monoclonal gammopathies: treatment update.

Authors:  Andreas J Steck; Adam Czaplinski; Susanne Renaud
Journal:  Neurotherapeutics       Date:  2008-10       Impact factor: 7.620

Review 5.  Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy.

Authors:  T Umapathi; Richard A C Hughes; Eduardo Nobile-Orazio; Jean-Marc Léger
Journal:  Cochrane Database Syst Rev       Date:  2015-03-04

6.  Long-term Effects of Intravenous Cyclophosphamide in Combination with Mesna Provided Intravenously and via Bladder Perfusion in a Patient with Severe Multifocal Motor Neuropathy.

Authors:  Eri Iwasawa; Takuya Ohkubo; Tadashi Kanouchi; Takashi Kanda; Hidehiro Mizusawa; Takanori Yokota
Journal:  Intern Med       Date:  2017-07-15       Impact factor: 1.271

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.